Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

10.40 +0.44 (+4.42%)
Streaming Delayed Price Updated: 1:03 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 424,401
Open 10.13
Bid (Size) 10.38 (300)
Ask (Size) 10.40 (500)
Prev. Close 9.960
Today's Range 9.871 - 10.43
52wk Range 5.455 - 16.19
Shares Outstanding 43,466,186
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The market is filled with gapping stocks in Friday's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill

Performance

YTD
-23.4%
-23.4%
1 Month
-29.9%
-29.9%
3 Month
+10.8%
+10.8%
6 Month
-3.5%
-3.5%
1 Year
+24.8%
+24.8%

More News

Read More
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Regenxbio (RGNX) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
What's going on in today's session ↗
Via Chartmill
Which stocks are gapping on Thursday? ↗
Via Chartmill
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire
News headline image
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 10.40
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 08/04/26 01:03 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 452.05M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 452M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.